Michael H Schiff
03.03.2015
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
Müller R, von Kempis J, Haile S, Schiff M. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015; 45:28-34.
03.03.2015Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
03.03.2015Semin Arthritis Rheum 2015; 45:28-34
Müller Rüdiger, von Kempis Johannes, Haile Sarah, Schiff Michael H
Weiter
27.06.2014
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Schiff M, von Kempis J, Goldblum R, Tesser J, Müller R. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 2014; 73:2174-7.
27.06.2014Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
27.06.2014Ann Rheum Dis 2014; 73:2174-7
Schiff Michael H, von Kempis Johannes, Goldblum Ronald, Tesser John R, Müller Rüdiger
Weiter